<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04028401</url>
  </required_header>
  <id_info>
    <org_study_id>RC19_0042</org_study_id>
    <nct_id>NCT04028401</nct_id>
  </id_info>
  <brief_title>Optimization of Skin Preparation to Reduce Cutibacterium Acnes Colonization in Superficial and Deep Samples During Prosthetic Shoulder Surgery in Male Patients</brief_title>
  <acronym>OPRICA</acronym>
  <official_title>Optimization of Skin Preparation to Reduce Cutibacterium Acnes Colonization in Superficial and Deep Samples During Prosthetic Shoulder Surgery in Male Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nantes University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nantes University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Infections on joint replacements remain one of the most serious complications of orthopaedic&#xD;
      surgery. Despite improvements in skin preparation and antibiotic prophylaxis procedures, the&#xD;
      risk of infection of joint prosthesis is still high, particularly for shoulder prostheses,&#xD;
      especially in men. One of the bacteria most often involved in post-operative infections for&#xD;
      shoulder prosthesis is Cutibacterium acnes (CA). This bacterium is one of the predominant&#xD;
      bacteria in pilosebaceous units. Eradication of this micro-organism remains difficult despite&#xD;
      the techniques used in the preoperative phase.&#xD;
&#xD;
      The objective of this protocol is to evaluate the efficacy of applying a 5% benzoyl peroxide&#xD;
      topical during the 5 days preceding the procedure in the surgical skin incision area, which&#xD;
      is based on local acne treatment, on the reduction of the CA bacterial load in the dermis of&#xD;
      the approach to shoulder arthroplasty in men.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 19, 2020</start_date>
  <completion_date type="Anticipated">June 2024</completion_date>
  <primary_completion_date type="Anticipated">June 2024</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of patients in each group with a positive Cutibacterium acnes sample at the dermis.</measure>
    <time_frame>Day 0</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Average number of positive intraoperative Cutibacterium acnes samples</measure>
    <time_frame>Day 0</time_frame>
    <description>samples taken at he cutaneous level before and after cutaneous antisepsis of the operating area before incision, fat and capsular.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Average number of positive Cutibacterium acnes skin samples before and after alcoholic surgical site antisepsis (5% alcoholic iodine povidone) in each of the two study groups</measure>
    <time_frame>Day 0</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Cutibacterium acnes shoulder prosthesis infections up to 2 years after shoulder prosthesis implantation in both study groups</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phylotype</measure>
    <time_frame>Day 0</time_frame>
    <description>Determination of phylotype by molecular typing by Multi-Locus Sequence Typing and Single-Locus Sequence Typing techniques and comparison of Cutibacterium acnes strains by molecular biology and characterization of antibiotic resistance</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cutibacterium acnes strains</measure>
    <time_frame>Day 0</time_frame>
    <description>Comparison of Cutibacterium acnes strains by molecular biology</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Antibiotic resistance</measure>
    <time_frame>Day 0</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of the skin tolerance of the topical application from the skin tolerance scale (irritation, erythema and desquamation), at the time of inclusion and at D0</measure>
    <time_frame>Day 0</time_frame>
    <description>skin tolerance scale evaluates local tolerance (absent: 0, light:1, moderate: 2 severe:3), erythema (absent:0, light:1, moderate:2, severe:3, very severe:4) and desquamation (absent: 0, light: 1, moderate: 2, severe: 3, very severe: 4)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">110</enrollment>
  <condition>Cutibacterium Acnes Infection</condition>
  <arm_group>
    <arm_group_label>5 % benzoyl peroxide topical treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Application of 5% benzoyl peroxide</description>
  </arm_group>
  <arm_group>
    <arm_group_label>No topical treatment</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>No intervention</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>5% benzoyl peroxide</intervention_name>
    <description>Application of 5% benzoyl peroxide during 5 days before the procedure</description>
    <arm_group_label>5 % benzoyl peroxide topical treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male patients, Adult patients,&#xD;
&#xD;
          -  Patient without a history of surgical intervention on the operated shoulder,&#xD;
&#xD;
          -  Patient managed for glenohumeral, partial (cup or anatomical hemi- arthroplasty) or&#xD;
             total (anatomical or inverted) glenohumeral arthroplasty placement for primary&#xD;
             osteoarthritis, or secondary to necrosis, massive rotator cuff tear or old fracture.&#xD;
&#xD;
          -  Patients affiliated to a social security system&#xD;
&#xD;
          -  Patients who have given their informed and written consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient with arthroplasty for resumption of previous shoulder surgery or failure of&#xD;
             arthroplasty&#xD;
&#xD;
          -  Patient with arthroplasty for acute trauma&#xD;
&#xD;
          -  Patient on immunosuppressantsimmunosuppressive drugs&#xD;
&#xD;
          -  Patient with inflammatory rheumatism&#xD;
&#xD;
          -  Patient with progressive cancer pathology&#xD;
&#xD;
          -  Allergies or intolerances concerning the modalities of selected skin preparations&#xD;
             (Povidone Iodine, cefazolin, hypersensitivity to benzoyl peroxide)&#xD;
&#xD;
          -  Dermatological pathologies in the area to be treated&#xD;
&#xD;
          -  Acne treatment in the area to be treated within four weeks before inclusion&#xD;
&#xD;
          -  Patient without possible help from a third party for the application of Cutacnyl® 5%&#xD;
             in the intervention group if necessary&#xD;
&#xD;
          -  Major under guardianship&#xD;
&#xD;
          -  Patient under the protection of justice&#xD;
&#xD;
          -  Patient not covered by social security&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stéphane CORVEC</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU de Nantes</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Stéphane CORVEC</last_name>
    <phone>0240083955</phone>
    <phone_ext>+33</phone_ext>
    <email>stephane.corvec@chu-nantes.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>CHU d'Angers</name>
      <address>
        <city>Angers</city>
        <zip>49933</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laurent HUBERT</last_name>
      <email>LaHubert@chu-angers.fr</email>
    </contact>
    <investigator>
      <last_name>Laurent HUBERT</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Brest</name>
      <address>
        <city>Brest</city>
        <zip>29609</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dominique LE NEN</last_name>
      <email>dominique.lenen@chu-brest.fr</email>
    </contact>
    <investigator>
      <last_name>Dominique LE NEN</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Nantes</name>
      <address>
        <city>Nantes</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stéphane CORVEC</last_name>
    </contact>
    <investigator>
      <last_name>Marc CAPELLI</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinique Saint Michel Sainte Anne</name>
      <address>
        <city>Quimper</city>
        <zip>29000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alexandre SONNARD</last_name>
      <email>a.sonnard@orange.fr</email>
    </contact>
    <investigator>
      <last_name>Alexandre SONNARD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Rennes</name>
      <address>
        <city>Rennes</city>
        <zip>35000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hervé THOMAZEAU</last_name>
      <email>herve.thomazeau@chu-rennes.fr</email>
    </contact>
    <investigator>
      <last_name>Hervé THOMAZEAU</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Locomoteur de l'Ouest</name>
      <address>
        <city>Saint-Grégoire</city>
        <zip>35760</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laurent BAVEREL</last_name>
      <email>l.baverel@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Laurent BAVEREL</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Santé Atlantique</name>
      <address>
        <city>Saint-Herblain</city>
        <zip>44819</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mathieu BOISSARD</last_name>
      <email>drboissard@polyclinique-atlantique.fr</email>
    </contact>
    <investigator>
      <last_name>Mathieu BOISSARD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Yves BOUJU</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Tours</name>
      <address>
        <city>Tours</city>
        <zip>37170</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Luc FAVARD</last_name>
      <email>luc.favard@univ-tours.fr</email>
    </contact>
    <investigator>
      <last_name>Luc FAVARD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHBA</name>
      <address>
        <city>Vannes</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David TOURAINE, Dr</last_name>
      <phone>02.97.01.42.56</phone>
      <email>david.touraine@ch-bretagne-atlantique.fr</email>
    </contact>
    <investigator>
      <last_name>David TOURAINE, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>July 17, 2019</study_first_submitted>
  <study_first_submitted_qc>July 18, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 22, 2019</study_first_posted>
  <last_update_submitted>November 17, 2021</last_update_submitted>
  <last_update_submitted_qc>November 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acne Vulgaris</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Benzoyl Peroxide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

